Japan Graves’ disease market is growing at a CAGR of around 4.7% during the forecast period. According to the WHO, around 10.1% of the country’s population is suffering from diabetes, among which, the individuals suffering from type-1 diabetes are more prone to develop Grave’s disease in the near future. According to IDF, around 2.2 per thousand children and adolescents aged 14 years and below are suffering from type-1 diabetes in Japan. Thus, the prevalence of disease is likely to propel the Japan Graves’ disease market growth during the forecast period.
To Request a Sample of our Report on Japan Graves’ disease Market: https://www.omrglobal.com/request-sample/japan-graves-disease-market
Further, the two regulatory agencies responsible for the Grave’s disease treatment products and services in Japan, includes, Ministry of Health Labor and Welfare (MHLW) and Pharmaceuticals and Medical Devices Agency (PMDA) which are responsible for the laws and regulation for medical devices & drugs and quality of pharmaceuticals and medical devices respectively.
According to the National Centre for Biotechnology Information (NCBI), in 2017, a range of childhood hyperthyroidism cases are accredited under Grave’s disease. Moreover, pediatric patients consist of less than 5% of the total number of patients that are suffering from Grave’s disease, wherein the prevalence rate of the disease in children and adolescents is around 0.02%. In Japan, around 40% of children have a familial history of the Graves’ disease, with frequency rate of 2% to 3%.
Additionally, Japan Thyroid Association is a Tokyo-based organization that consists of a range of scientists that develop guidelines for the diagnosis and management of thyroid nodules. The committee is further organized in the examination of the prevalence of subclinical hypothyroidism in Japan. The organization has provided “Guidelines for the Treatment of Grave’s Disease with Anti-thyroid Drug, in 2006”, stating several standard therapeutic protocols to general physicians for the treatment of Grave’s disease. Thus, such standard set by the government in Japan has created scope for the Japan Graves’ disease market growth in the near future.
(Get 15% Discount on Buying this Report)
A full Report Japan Graves’ disease Market is Available @ https://www.omrglobal.com/industry-reports/japan-graves-disease-market
Japan Graves’ disease Market Segmentation
By Diagnosis
- Ultrasound
- Imaging Tests
- Radioactive Iodine Uptake
- Blood Sample
By Treatment
- Anti- Thyroid Medication
- Radioactive Iodine Therapy
- Surgery
Company Profiles
- Abbott Laboratories Inc.
- Allergan PLC
- Eli Lilly and Co.
- GlaxoSmithKline PLC
- Johnson & Johnson
- Macleods Pharmaceuticals Ltd.
- Merck & Co. Inc.
- Mylan NV
- Novartis International AG
- Pfizer Inc.
- Sanofi SA
- Takeda Pharmaceutical Co. Ltd.
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
